Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
George Golumbeski
AddedFeb 13, 2024
UpdatedMay 31, 2026
George Golumbeski

George Golumbeski

Board Member, MorphoSys

The Org

George Golumbeski's Career

MorphoSys
MorphoSys

Planegg, Bavaria, DE

Board Member· Board
BlackThorn Therapeutics
BlackThorn Therapeutics

San Francisco, CA, US

Board Member· Board
KSQ Therapeutics
KSQ Therapeutics

Cambridge, MA, US

Board Member· Board
GRAIL
GRAIL

Menlo Park, CA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

George Golumbeski's Career

MorphoSys
MorphoSys
Public$668.7M6151992Planegg, Bavaria, DE
Board Member· Board

Leadership at MorphoSys

Simon MoroneySimon MoroneyCo-Founder
Andreas PlückthunAndreas PlückthunCo-Founder
Marc CluzelMarc CluzelBoard Member
Wendy JohnsonWendy JohnsonBoard Member
Andrew ChengAndrew ChengBoard Member
Jean-Paul KressJean-Paul KressBoard Member
BlackThorn Therapeutics
BlackThorn Therapeutics
Acquired$138M02015San Francisco, CA, US
Board Member· Board

Leadership at BlackThorn Therapeutics

Lori HuLori HuBoard Member
Alex TkachenkoAlex TkachenkoFounder
Julie SunderlandJulie SunderlandBoard Member
Mark H N CorriganMark H N CorriganBoard Member
Kristina BurowKristina BurowBoard Member
Paul L. BernsPaul L. BernsBoard Member
KSQ Therapeutics
KSQ Therapeutics
Series C$156M852015Cambridge, MA, US
Board Member· Board

Leadership at KSQ Therapeutics

Mahesh KarandeMahesh KarandeBoard Member
David M. SabatiniDavid M. SabatiniFounder
Frank StegmeierFrank StegmeierBoard Member
Pearl HuangPearl HuangBoard Member
Theo Melas-KyriaziTheo Melas-KyriaziBoard Member
Richard MoscickiRichard MoscickiBoard Member

Similar to KSQ Therapeutics

NKT TherapeuticsNKT TherapeuticsWaltham, MA, USTherapeuticsest. 2008NKT TherapeuticsWaltham, MA, US · est. 2008

NKT Therapeutics: A US-based biotech firm dedicated to developing treatments for cancer and serious diseases.

Series A · $12M8
Nested TherapeuticsNested TherapeuticsCambridge, MA, USTherapeuticsest. 2021Nested TherapeuticsCambridge, MA, US · est. 2021

Nested Therapeutics: A biotech innovator designing impactful therapeutics through creative service.

Series A · $125M50
Celsius TherapeuticsCelsius TherapeuticsCambridge, MA, USTherapeuticsest. 2018Celsius TherapeuticsCambridge, MA, US · est. 2018

Celsius Therapeutics, a US-based biotech firm, develops drugs for cancer and autoimmune diseases.

Series B · $148M72
Quanta TherapeuticsQuanta TherapeuticsSan Francisco, CA, USCancer Therapeuticsest. 2018Quanta TherapeuticsSan Francisco, CA, US · est. 2018

Quanta, founded in 2018, is a San Francisco-based biotech firm specializing in novel cancer therapeutics.

Series D · $140.7M28
GRAIL
GRAIL
Public$2B8232016Menlo Park, CA, US
Board Member· Board

Recent news

Littlebird raises $11M for its AI-assisted ‘recall’ tool that reads your computer screenTechCrunch · 2026

Leadership at GRAIL

Brook ByersBrook ByersBoard Member
Jeff DeanJeff DeanBoard Member
Jeff HuberJeff HuberBoard Member
Bob RagusaBob RagusaCEO
William H. RastetterWilliam H. RastetterBoard Member
Maykin HoMaykin HoBoard Member

Similar to GRAIL

FreenomeFreenomeSouth San Francisco, CA, USCancer Detectionest. 2014FreenomeSouth San Francisco, CA, US · est. 2014

Freenome, a US-based company, is dedicated to providing tools for cancer detection, treatment, and prevention.

Late Stage Private · $1.1B375
Guardant HealthGuardant HealthPalo Alto, CA, USCancer Diagnosticsest. 2011Guardant HealthPalo Alto, CA, US · est. 2011

Guardant Health: A Palo Alto-based biotech firm providing global cancer diagnostics and sequencing services.

Public1.8k
Thrive Earlier DetectionThrive Earlier DetectionCambridge, MA, USCancer Detectionest. 2019Thrive Earlier DetectionCambridge, MA, US · est. 2019

Thrive, a healthcare company, pioneers in early cancer detection through its innovative test, CancerSEEK.

Late Stage Private · $367M175
Exact SciencesExact SciencesMadison, WI, USCancer Diagnosticsest. 1995Exact SciencesMadison, WI, US · est. 1995

Exact Sciences Corp., a US-based firm, develops non-invasive tests for early colorectal cancer detection.

Public · $2.1B6.4k

George Golumbeski's Similar Executives & Operators

Lau Eng BoonLau Eng BoonBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoSean JohSean JohBoard Member · Kakao

People Similar to George Golumbeski

Jim MullenJim MullenBoard Member · Thermo Fisher thMichael SingerMichael SingerBoard Member · iVexSolDaniel LynchDaniel LynchBoard Member · Blueprint MedicinesDaniel WelchDaniel WelchBoard Member · Ultragenyx PharmaceuticalGarry NicholsonGarry NicholsonBoard Member · NextCureMike BonneyMike BonneyBoard Member · Alnylam Pharmaceuticals aln